siRNA targeting EHD2 gene and its application
By designing siRNA molecules targeting the EHD2 gene, the problem of limited efficacy in the treatment of non-small cell lung cancer in the existing technology has been solved, significantly reduced the EHD2 expression level, promoted the proliferation and migration of lung cancer cells, activated the EMT pathway, and established a lung cancer growth-related model. , help study the pathogenesis of lung cancer.
Patent Information
- Application Number
- CN202111141176.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-27
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-09-27
AI Technical Summary
The efficacy of the prior art in the treatment of non-small cell lung cancer is affected by a variety of factors, and the 5-year survival rate of lung cancer patients is not high, and there is a lack of effective targeted treatment methods, especially the targeted treatment plans for the EHD2 gene are insufficient.
A siRNA molecule targeting the EHD2 gene was designed, and double-stranded RNA molecules such as 5′-UCCGCAAACUCAACCCUUUdTdT-3′ and 5′-AAAGGGUUGAGUUUGCGGAdTdT-3′ are used to promote lung cancer cell proliferation, migration, invasion and activation of EMT through nucleic acid sequences such as 5′-UCCGCAAACUCAACCCUUUdTdT-3′ and 5′-AAAGGGUUGAGUUGCGGAdTdT-3′. pathways, thereby establishing a related model for lung cancer growth.
It significantly reduces the expression level of EHD2 in lung cancer cells, promotes cell proliferation and migration, and activates the EMT pathway, providing experimental basis to in-depth study of the role of EHD2 gene in malignant tumors, and helps to study the pathogenesis of lung cancer from the molecular level.
Smart Images

Figure CN114075563B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to siRNA targeting EHD2 gene and application thereof. Background Art
[0002] Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer is the most common type of lung cancer, accounting for about 85% of the total number of cases. In recent years, the prognosis of lung cancer patients has been greatly improved through surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy. However, due to the high incidence of recurrence, metastasis and drug resistance after treatment, the 5-year survival rate of lung cancer patients does not exceed 20%. Radiotherapy is the most important non-surgical treatment for non-small cell lung cancer, but its efficacy is still affected by many factors, such as tumor epithelial-mesenchymal transition, intrinsic radiation resistance of tumors, heterogeneity of tumor cells, tumor microenvironment and immune response. Therefore, it is particularly important to explore new key target genes and therapeutic targets and improve the efficacy of radiotherapy for the treatment of non-small cell lung cancer.
[0003] EHD2 (EH-domian containing protein 2), as an important member of the EHD family, is a membrane transport regulatory protein containing an EH domain at the C-terminus. It has the functions of signal transduction and regulating the endocytosis of membrane proteins and membrane receptors. Reports in recent years have shown that EHD2 is associated with a variety of cancers. In liver cancer, EHD2 interacts with E-cadherin. When stimulated by mechanical stress or radiation, pits disintegrate, forming E-cadherin vesicles that enter the cell and are degraded in the lysosome or recycled to the plasma membrane, recruiting EHD2 to stabilize it at the plasma membrane. E-cadherin loss is a key event in EMT in vivo. In lung cancer, breast cancer, and ovarian cancer, the downregulation of E-cadherin leads to reduced cell-to-cell adhesion, which is an important feature of tumor progression. Summary of the invention
[0004] In view of the above problems existing in the prior art, the technical problem to be solved by the present invention is to provide a siRNA targeting the EHD2 gene. Another technical problem to be solved by the present invention is to provide the use of the above siRNA targeting the EHD2 gene in establishing a lung cancer growth-related model.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0006] An siRNA molecule targeting the EHD2 gene is a double-stranded RNA molecule having the following nucleic acid sequence:
[0007] Sense sequence: 5′-UCCGCAAACUCAACCCUUUdTdT-3′,
[0008] Antisense sequence: 5′-AAAGGGUUGAGUUUGCGGAdTdT-3′;
[0009] or
[0010] Sense sequence: 5′-GGAAGGAGAACAAGAAGAAdTdT-3′,
[0011] Antisense sequence: 5′-UUCUUCUUGUUCUCCUUCCdTdT-3′;
[0012] or
[0013] Sense sequence: 5′-CCAAAUACGACGAGAUCUUdTdT-3′,
[0014] Antisense sequence: 5′-AAGAUCUCGUCGUAUUUGGdTdT-3′.
[0015] The use of the siRNA molecule targeting EHD2 in at least one of the following (a)-(d):
[0016] (a) promoting the proliferation of lung cancer cells, or preparing a product for promoting the proliferation of lung cancer cells;
[0017] (b) promoting the migration of lung cancer cells, or preparing a product for promoting the migration of lung cancer cells;
[0018] (c) promoting the invasion of lung cancer cells, or preparing a product for promoting the invasion of lung cancer cells;
[0019] (d) activating the EMT pathway in lung cancer cells, or preparing a product for activating the EMT pathway in lung cancer cells.
[0020] The product for promoting lung cancer cell proliferation is a lung cancer cell model with enhanced proliferation ability, or a substance for preparing a lung cancer cell model with enhanced proliferation ability.
[0021] The product for promoting lung cancer cell migration is a lung cancer cell model with enhanced migration ability, or a substance for preparing a lung cancer cell model with enhanced migration ability.
[0022] The product for promoting lung cancer cell proliferation is a lung cancer cell model with enhanced proliferation ability, or a substance for preparing a lung cancer cell model with enhanced proliferation ability.
[0023] The product for activating the EMT pathway in lung cancer cells is a lung cancer cell model in which the EMT pathway is activated in lung cancer cells, or is a substance for preparing a model in which the EMT pathway is activated in lung cancer cells.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention designs specific siRNA to block EHD2, which can significantly reduce the expression level of EHD2 in lung cancer cells, significantly promote cell proliferation, migration and EMT pathway activation, thereby promoting the growth of lung cancer cells. The siRNA molecules targeting EHD2 provided by the present invention can be used to establish a lung cancer growth-related model, help to clarify the role of the EHD2 gene and its target gene, provide experimental basis for in-depth research on its role in various physiological and pathological processes, help to clarify the development law of EHD2 transcription factors in malignant tumors, and provide help for studying the pathogenesis of lung cancer at the molecular level. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The result diagram of the expression level of EHD2 in lung cancer cell A549 and after siRNA interference;
[0027] Figure 2 This is a result diagram of CCK8 experiment proving that siEHD2 affects the proliferation of lung cancer cells;
[0028] Figure 3 This is a result of the Transwell migration experiment proving that siEHD2 affects the metastasis of lung cancer cells;
[0029] Figure 4 The results are shown to demonstrate the effect of siEHD2 on the expression levels of EMT-related proteins;
[0030] Figure 5 This is the plasmid map of the EHD2 lentiviral overexpression vector;
[0031] Figure 6 The results of protein immunoblotting experiments of cells in the 1v-EHD2 group and the control group (NC);
[0032] Figure 7 This is a graph showing the CCK8 experimental results of cells in the 1v-EHD2 group and the control group (NC);
[0033] Figure 8 This is the result of Transwell cell migration experiment of lvEHD2 group and control group (NC);
[0034] Fig. 9 This is the result graph of the expression levels of EMT-related proteins in the cell control group (NC) of the lvEHD2 group. DETAILED DESCRIPTION
[0035] The present invention is further described below in conjunction with specific embodiments.
[0036] Example 1: Design of interfering siRNA against EHD2
[0037] Three siRNA sequences and a control sequence were designed for the human EHD2 gene (GenBank ID: NM_014601.4). The siRNA and the control were chemically synthesized by Heyuan Biotechnology Co., Ltd.
[0038] The base sequence of siRNA1 is:
[0039] 5′-UCCGCAACUCAACCCUUUdTdT-3′,
[0040] 5′-AAAGGGUUGAGUUUGCGGAdTdT-3′:
[0041] The base sequence of siRNA2 is:
[0042] 5′-GGAAGGAGAACAAGAAGAAdTdT-3′,
[0043] 5′-UUCUUCUUGUUCUCCUUCCdTdT-3′;
[0044] The base sequence of siRNA3 is:
[0045] 5′-CCAAAUACGACGAGAUCUUdTdT-3′,
[0046] 5′-AAGAUCUCGUCGUAUUUGGdTdT-3′;
[0047] The base sequence of the siRNA control group is:
[0048] 5′-UUCUCCGAACGUCACGUdTdT-3′
[0049] 5′-ACGUGACGUUCGGAGAAdTdT-3′
[0050] Example 2: Screening and functional verification of EHD2 interfering siRNA
[0051] 1. Cell culture
[0052] The A549 non-small cell lung cancer cell line used in the experiment of the present invention was purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
[0053] First, preheat the water bath to 37°C, open the clean bench, wipe with 75% alcohol, and then disinfect with ultraviolet light for 30 minutes. Take out the A549 cell line from the -80°C ultra-low temperature refrigerator, quickly put the cryotube into the preheated water bath to quickly thaw, and shake it continuously to melt the liquid in the tube quickly. After thawing, put the cryotube into the centrifuge and centrifuge at 1000rpm / min for 2 to 5 minutes. Put the cryotube into the clean bench, open it, remove the supernatant, resuspend it with complete culture medium, transfer it to a 25mm culture bottle, shake it evenly using the cross method, observe the distribution of cells under a microscope to ensure that the cells are evenly distributed, and finally put the culture bottle at 37°C, containing 5% CO 2 After overnight incubation in a humidified incubator, the medium change time is determined according to the cell condition.
[0054] 2. Cell passaging
[0055] A549 non-small cell lung cancer cell line was cultured for 1-2 days. When the cells adhered to the wall and grew to a density of about 85% under a microscope, the culture medium was discarded, and 1 mL of 0.25% trypsin was added after rinsing 2-3 times with PBS (1×). When about 50% of the adherent cells were observed to float up under a microscope, a certain amount of stop solution was added, and then the cells were dispersed by blowing in a clockwise order. Finally, the digested cell suspension was placed in a 15 mL centrifuge tube and centrifuged at 1000 rpm / min for 2-5 min. After discarding the supernatant, the culture medium was added and the cells were resuspended, and re-inoculated into a new culture bottle at a ratio of 1:2-1:3 for continued culture.
[0056] 3. Cell transfection
[0057] Adherent cells: 24 hours before transfection, prepare cell suspension using complete medium without double antibody, mix thoroughly and measure the required cell concentration using a cell counter. Inoculate in a six-well plate to ensure that the cell density in each well is about 50% at the time of transfection.
[0058] Dilute siRNA with 50μL Opti-MEM (the final concentration of transfected cells is 50nM), and gently pipette 3-5 times to mix. Gently invert to mix the transfection reagent, dilute 1.0μL LipofectamineTM 2000 with 50μL Opti-MEM, and gently pipette 3-5 times to mix, and let stand at room temperature for 5min. Mix the transfection reagent and siRNA dilution, and gently pipette 3-5 times to mix, and let stand at room temperature for 20min. Mix the Opti-MEM containing siRNA1, siRNA2, and siRNA3 and the siRNA transfection reagent, and then slowly add them to the corresponding 24-well cell plate, 100μL / well, and gently shake the cell plate back and forth to mix evenly. Place the cell plate at 37℃, 5% CO 2Culture in an incubator for 18-48 hours. Replace with fresh culture medium 4-6 hours after transfection.
[0059] 4. Western Blotting
[0060] Western blot analysis was performed to verify whether the expression of the target gene EHD2 in lung cancer cells was inhibited after transfection of siRNA. Normal A549 lung cancer cells and three groups of stable transfection cells were cultured separately. The A549 lung cancer cell line transfected with siRNA was treated with lysis buffer and homogenized to obtain cell lysate. The total protein was separated by 10% SDS-polyacrylamide gel electrophoresis (room temperature, 120-150V, 120min), and the polyacrylamide gel was taken out for PVDF membrane electrotransfer (4°C, 300mA, 90min). The PVDF membrane was taken out and placed in 5% skim milk blocking solution, and blocked at room temperature for about 2h; anti-EHD2 antibody (purchased from abcam) was added as the primary antibody and incubated at room temperature for about 2h. Then rabbit antibody (CST) was added as the secondary antibody and incubated at room temperature for about 2h. Finally, chemically enhanced luminescence reagent was added for development, and GAPDH was used as the internal reference. The results are shown in the figure. Figure 1 shown.
[0061] It can be seen from the results of the protein blotting experiment that compared with the expression level of EHD2 protein in the negative control NC group, the bands of the transfected siRNA1 group, siRNA2 group and siRNA3 group were weakened, indicating that the expression level of EHD2 protein after transfection was inhibited, and the protein level inhibition effect of the transfected siRNA3 group was significant.
[0062] In summary, it was found that siRNA3 had the most significant inhibitory effect on EHD2 protein, so the small interfering RNA in the following experiments 5-7 refers to siRNA3.
[0063] 5. CCK-8 cell proliferation assay
[0064] To verify the effect of siEHD2 on lung cancer cell proliferation, CCK-8 cell proliferation assay was used:
[0065] The A549 cells transfected with small interfering RNA and the cells in the negative control group were digested, centrifuged at low speed, and resuspended in complete medium. The cell counting instrument adjusted the number of cells in the samples to a consistent number in batches, and the number of cells per well in the 96-well plate was about 4×10 3 , 100 μL of culture medium per well. Set up 3 replicate wells for the experimental group, and set up complete culture medium as a blank control group. Shake well by cross method, and observe the cell distribution under a microscope to ensure that the cells are evenly distributed, without accumulation or overlap. Then transfer them to 37°C with 5% CO 2After overnight incubation, add 10 μL of CCK-8 reagent to each well and transfer to a 37°C, 5% CO incubator. 2 Culture the cells in a cell culture incubator for 24-96 hours. Measure the absorbance at 450 nm at 24, 48, 72, and 96 hours according to the instructions of the microplate reader, record the OD value, and draw a proliferation curve based on the data. Figure 2 As shown in the results of CCK-8 cell proliferation experiment, compared with the control group (NC), the OD values of the cells in the si-EHD2 group were significantly increased at 48h, 72h and 96h of detection (p<0.05).
[0066] 6. To verify the effect of EHD2 siRNA on the migration ability of lung cancer cells, Transwell cell migration assay was used:
[0067] Digest the target cells in sequence, centrifuge, resuspend the target cells with PBS (1×), wash again, remove the upper liquid after centrifugation, and finally resuspend the cells with serum-free medium. Take the serum-free medium cell mother solution to count the cells, and adjust the cell density with serum-free medium to reach the target cell number, about 3×10 5 . Use a sterile 24-well plate, place 500mL of complete culture medium (containing 10% fetal bovine serum) in the lower chamber, and place the small chamber in the corresponding 24-well plate. Add the cell suspension mother solution, the volume is about 200μL, shake gently, and finally place it in the cell culture incubator for 24h. After the specified time, take out the 24-well plate, add about 600mL of 4% paraformaldehyde to the blank well, rinse the small chamber with PBS and put it in for fixation for 20min. After fixation, rinse slowly with PBS, air-dry appropriately, and stain with crystal violet stain (0.1%) for 30min. Gently take out the small chamber, wash it with PBS 2-3 times, and then wipe the cells that have not migrated in the upper chamber with a cotton swab. After drying, observe and take pictures under a microscope. The number of migrated cells in the control group (NC) and the siEHD2 group was analyzed by Prism8.0. P values less than 0.05 were statistically significant. The results are as follows Figure 3 As shown: Through the Transwell cell migration experiment, Figure 3 The two groups of pictures on the left are experimental microscopic images of migration and invasion in the NC group and the siEHD2 group. Figure 3 The two groups of figures on the right are bar graphs comparing the migration and invasion abilities of the NC group and the siEHD2 group. The results showed that compared with the NC group, the number of migrating and invading cells in the siEHD2 group increased significantly, and the migration ability was significantly enhanced (P < 0.05).
[0068] 7. To verify the effect of siEHD2 on the epithelial-mesenchymal transition (EMT) of cells, the protein imprinting experiment method was used to detect the expression levels of EMT-related molecules.
[0069] Normal A549 lung cancer cells (NC) and siEHD2 group A549 lung cancer cells were cultured separately. The A549 lung cancer cell line transfected with siRNA was treated with lysis buffer and homogenized to obtain cell lysate. The total protein was separated by 10% SDS-polyacrylamide gel electrophoresis (room temperature, 120-150V, 120min), and the polyacrylamide gel was taken out for PVDF membrane electrotransfer (4℃, 300mA, 90min). The PVDF membrane was taken out and placed in 5% skim milk blocking solution, and blocked at room temperature for about 2h. The primary antibody was added and incubated at room temperature for about 2h. The secondary antibody was added and incubated at room temperature for about 2h. Finally, the chemical enhanced luminescence reagent was added for development, and GAPDH was used as the internal reference control. As shown in 4, compared with the control group (NC), the protein expression level of E-cadherin in the siEHD2 group was significantly weakened, but the protein expression levels of N-cadherin and Vimentin were slightly increased. The results show that knockdown of siEHD2 can activate the EMT pathway.
[0070] Example 3: Effects of a lentiviral overexpression vector on the behavior of EHD2 in non-small cell lung cancer cells
[0071] 1. The construction and identification of the EHD2 inducible expression virus vector was commissioned to Heyuan Biotechnology Co., Ltd. The plasmid map of the vector is as follows Figure 5 The construction steps are as follows: the vectors used are all H19127 vectors, and the element sequence is: GL119 pSLenti-CMV-MCS-3xFLAG-PGK-Puro-WPRE. The upstream and downstream cloning restriction sites EcoRI and XmaI are used for restriction digestion, and then the digested vector is recovered by agarose gel electrophoresis. The corresponding primers are used for PCR amplification to obtain the full-length gene fragment of EHD2. The corresponding relationship of the primers is shown in the following table:
[0072] Sense sequence: 5′-CGCAAATGGGCGGTAGGCGTG-3′,
[0073] Antisense sequence: 5′-AAGAACGGAGCCGGTTGGCG-3′.
[0074] 2. Western Blotting Experimental Method
[0075] Verify the effect of EHD2 expression in stable cell lines overexpressing EHD2. Normal H1299 lung cancer cells and overexpression stable cell groups were cultured separately. The lung cancer cell line overexpressing EHD2 was treated with lysis buffer and homogenized to obtain cell lysate. The total protein was separated by 10% SDS-polyacrylamide gel electrophoresis (room temperature, 120-150V, 120min), and the polyacrylamide gel was taken out for PVDF membrane electrotransfer (4°C, 300mA, 90min). The PVDF membrane was taken out and placed in 5% skim milk blocking solution, and blocked at room temperature for about 2h; anti-EHD2 antibody (purchased from abcam) was added as the primary antibody and incubated at room temperature for about 2h. Then rabbit antibody (CST) was added as the secondary antibody and incubated at room temperature for about 2h. Finally, chemically enhanced luminescence reagent was added for development, and GAPDH was used as the internal reference. The results are as follows Figure 6 As shown in the results of the Western blot experiment, it can be seen that compared with the expression level of EHD2 protein in the negative control NC group, the band of overexpressed EHD2 is significantly enhanced, indicating that the protein expression level of EHD2 mediated by the lentiviral overexpression vector is significantly upregulated.
[0076] 3. CCK-8 cell proliferation assay
[0077] To verify the effect of lvEHD2 on lung cancer cell proliferation, a CCK-8 cell proliferation experiment was performed: the H1299 lung cancer cell line and the negative control group cells mediated by lentiviral overexpression vector EHD2 were digested, centrifuged at low speed, and the target cells were resuspended in complete culture medium. The cell counting instrument adjusted the number of sample cells to a consistent level in batches, with approximately 4×103 cells per well in a 96-well plate and 100 μL of culture medium per well. Three replicate wells were set up in the experimental group, and a complete culture medium was set up as a blank control group. The cells were shaken evenly using the cross method, and the cell distribution could be observed under a microscope to ensure that the cells were evenly distributed, without accumulation or overlap. They were then transferred to a 37°C, 5% CO 2 After overnight incubation, add 10 μL of CCK-8 reagent to each well and transfer to a 37°C, 5% CO incubator. 2 Culture the cells in a cell culture incubator for 24-96 hours. Measure the absorbance at 450 nm at 24, 48, 72, and 96 hours according to the instructions of the microplate reader, record the OD value, and draw a proliferation curve based on the data. Figure 7 As shown in the results of CCK-8 cell proliferation experiment, compared with the control group (NC), the OD values of the cells in the 1v-EHD2 group were significantly reduced at 48h, 72h and 96h of detection (p<0.05).
[0078] 4. To verify the effect of overexpression of EHD2 on the migration ability of lung cancer cells, a Transwell cell migration assay was performed: the target cells were digested and centrifuged in sequence, and the target cells were resuspended in PBS (1×), washed again, and the upper liquid was removed after centrifugation. Finally, the cells were resuspended in serum-free medium. The serum-free medium cell mother solution was taken for cell counting, and the cell density was adjusted to the target cell number, about 3×10 5 . A sterile 24-well plate was used, and 500 mL of complete culture medium (containing 10% fetal bovine serum) was placed in the lower chamber, and the small chamber was placed in the corresponding 24-well plate. The cell suspension mother solution was added, with a volume of about 200 μL, and it was shaken slightly, and finally placed in a cell culture incubator for 24 hours. After the specified time, the 24-well plate was taken out, and about 600 mL of 4% paraformaldehyde was added to the blank well. The small chamber was rinsed with PBS and then placed in for fixation for 20 minutes. After fixation, it was slowly rinsed with PBS, and after proper air drying, it was stained with crystal violet stain (0.1%) for 30 minutes. Gently take out the small chamber, wash it with PBS 2-3 times, and then wipe the cells that have not migrated in the upper small chamber with a cotton swab. After drying, it was observed and photographed under a microscope. The number of migrating cells in the control group (NC) and the lvEHD2 group was analyzed by Prism8.0. P values less than 0.05 were statistically significant. The results are as follows Figure 8 As shown: Through the Transwell cell migration experiment, Figure 8 The two groups of pictures on the left are experimental microscopic images of migration and invasion in the NC group and the lvEHD2 group. Figure 8 The two groups of figures on the right are bar graphs comparing the migration and invasion abilities of the NC group and the lvEHD2 group. The results showed that compared with the NC group, the number of migrating and invasive cells in the lvEHD2 group was significantly reduced, and the migration ability was significantly inhibited (P < 0.05).
[0079] 5. To verify the effect of lvEHD2 on the epithelial-mesenchymal transition (EMT) process of cells, the expression level of EMT-related molecules was detected by protein blotting. Normal H1299 lung cancer cells (NC) and lvEHD2 group H1299 lung cancer cells were cultured separately. The overexpressed H1299 lung cancer cell line was treated with lysis buffer and homogenized to obtain cell lysate. The total protein was separated by 10% SDS-polyacrylamide gel electrophoresis (room temperature, 120-150V, 120min), and the polyacrylamide gel was taken out for PVDF membrane electrotransfer (4°C, 300mA, 90min). The PVDF membrane was taken out and placed in 5% skim milk blocking solution, and blocked at room temperature for about 2h. The primary antibody was added and incubated at room temperature for about 2h. The secondary antibody was added and incubated at room temperature for about 2h. Finally, the chemically enhanced luminescence reagent was added for development, with GAPDH as the internal reference. The results are as follows Fig. 9 As shown in the figure, compared with the control group (NC), the protein expression level of E-cadherin in the lvEHD2 group was significantly enhanced, but the protein expression levels of N-cadherin and Vimentin were slightly reduced. The results showed that overexpressed EHD2 could inhibit the EMT pathway. Sequence Listing <110> Nantong Cancer Hospital <120> siRNA targeting EHD2 gene and its application <130> 100 <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 19 <212> RNA <213> siRNA1-F(Artificial) <400> 1 uccgcaaacu caacccuuu 19 <210> 2 <211> 19 <212> RNA <213> siRNA1-R(Artificial) <400> 2 aaaggguuga guuugcgga 19 <210> 3 <211> 19 <212> RNA <213> siRNA2-F(Artificial) <400> 3 ggaaggagaa caagaagaa 19 <210> 4 <211> 19 <212> RNA <213> siRNA2-R(Artificial) <400> 4 uucuucuugu ucuccuucc 19 <210> 5 <211> 19 <212> RNA <213> siRNA3-F(Artificial) <400> 5 ccaaauacga cgagaucuu 19 <210> 6 <211> 17 <212> RNA <213> siRNA3-R(Artificial) <400> 6 acgugacguu cggagaa 17
Claims
1. Use of siRNA molecules targeting EHD2 in at least one of the following (a)-(d): (a) preparing a product for promoting lung cancer cell proliferation; the product for promoting lung cancer cell proliferation is a lung cancer cell model with enhanced proliferation ability, or a substance for preparing a lung cancer cell model with enhanced proliferation ability; (b) preparing a product for promoting lung cancer cell migration; the product for promoting lung cancer cell migration is a lung cancer cell model with enhanced migration ability, or a substance for preparing a lung cancer cell model with enhanced migration ability; (c) preparing a product for promoting lung cancer cell invasion; the product for promoting lung cancer cell proliferation is a lung cancer cell model with enhanced proliferation ability, or a substance for preparing a lung cancer cell model with enhanced proliferation ability; (d) preparing a product for activating the EMT pathway in lung cancer cells; the product for activating the EMT pathway in lung cancer cells is a lung cancer cell model in which the EMT pathway is activated in lung cancer cells, or a substance for preparing a model of activation of the EMT pathway in lung cancer cells; The siRNA molecule targeting the EHD2 gene is a double-stranded RNA molecule with the following nucleic acid sequence: Sense sequence: 5′-CCAAAUACGACGAGAUCUUdTdT-3′, Antisense sequence: 5′-AAGAUCUCGUCGUAUUUGGdTdT-3′; The lung cancer cells are A549 and / or H1299.
